GO:0050855 regulation of B cell receptor signaling pathway: Signaling Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050855 describes any process that modulates the frequency, rate or extent of signaling pathways initiated by cross-linking of an antigen receptor on a B cell.
• The B cell receptor (BCR) is a multiprotein complex containing membrane immunoglobulin and the signaling subunits Igα (CD79a) and Igβ (CD79b).
• BCR signaling is controlled by kinases such as Bruton's tyrosine kinase (BTK), phosphatases, ubiquitin ligases such as KLHL14, and microRNAs.
• Dysregulated BCR signaling contributes to B cell malignancies, autoimmunity, and immunodeficiency, making this pathway a major therapeutic target.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of regulators within this GO term.
• Understanding GO:0050855 supports drug discovery, biomarker development, and functional genomics in immunology and oncology.
Description
The Gene Ontology term GO:0050855, regulation of B cell receptor signaling pathway, refers to any process that modulates the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B cell. B cells recognize antigen through the B cell receptor (BCR), a surface complex that converts extracellular antigen binding into intracellular signals controlling survival, proliferation, differentiation, and antibody production. Because the BCR is central to adaptive immunity, its signaling must be tightly regulated to avoid autoimmunity, immunodeficiency, and malignant transformation. This article integrates the QuickGO definition with published literature to explain the mechanisms, key genes, disease links, and research methods relevant to GO:0050855.
regulation of B cell receptor signaling pathway At A Glance
| GO ID | GO:0050855 |
|---|---|
| GO term | regulation of B cell receptor signaling pathway |
| Ontology | biological_process |
| Definition | Any process that modulates the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B cell. |
| Synonyms | regulation of B-cell receptor signaling pathway; regulation of B cell receptor signalling pathway; regulation of B-cell receptor signalling pathway; regulation of B lymphocyte receptor signaling pathway; regulation of B-lymphocyte receptor signaling pathway; regulation of B lymphocyte receptor signalling pathway; regulation of B-lymphocyte receptor signalling pathway |
| Major function | Modulates BCR-proximal signal transduction to control B cell activation, survival, proliferation, and differentiation. |
| Key regulators | BTK, SYK, LYN, CD79A, CD79B, PTPN6, KLHL14, and microRNAs. |
| Disease relevance | B cell malignancies, autoimmunity, and immunodeficiency. |
What Is GO:0050855?
GO:0050855 is a biological process term defined as any process that modulates the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a B cell. In practice, it covers positive and negative regulators that act on BCR-proximal signaling, including kinases, phosphatases, adaptor proteins, ubiquitin ligases, and transcriptional or microRNA-mediated control of BCR signaling components.
Why Is regulation of B cell receptor signaling pathway Important in Cell Biology?
GO:0050855 is important because BCR signaling is a central checkpoint in humoral immunity, and its dysregulation is directly linked to diseases such as chronic lymphocytic leukemia, diffuse large B cell lymphoma, rheumatoid arthritis, and primary immunodeficiencies. Pharmacological inhibition of BCR signaling kinases, notably BTK, has validated this pathway as a therapeutic target. Therefore, researchers studying GO:0050855 need robust experimental models to identify and characterize regulators of BCR signaling.
• Controls B cell activation, survival, and antibody responses.
• Dysregulation is a hallmark of B cell malignancies such as CLL and DLBCL.
• BTK inhibitors demonstrate the clinical value of targeting BCR signaling.
• MicroRNAs fine-tune BCR signaling and influence autoimmunity and cancer.
• Ubiquitin ligases such as KLHL14 regulate BCR-dependent NF-κB signaling.
• Glucocorticoids modulate BCR signaling components in aggressive lymphomas.
• Provides a framework for functional genomics of immune signaling.
• Supports development of biomarkers and combination therapies.
What Happens During regulation of B cell receptor signaling pathway?
Antigen recognition and BCR cross-linking
In simple terms: The B cell receptor binds antigen, and multiple receptors cluster together to start signaling.
BCR signaling begins when membrane immunoglobulin binds antigen and cross-links, bringing associated Igα (CD79a) and Igβ (CD79b) subunits into close proximity. This clustering enables phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) in CD79a and CD79b by Src-family kinases such as LYN. The QuickGO definition of GO:0050855 explicitly refers to signaling initiated by cross-linking of an antigen receptor on a B cell.
Proximal kinase activation and signalosome assembly
In simple terms: Enzymes are recruited to the activated receptor and build a signaling platform.
Phosphorylated ITAMs recruit SYK, which activates downstream adaptors and kinases including BTK. BTK is a critical cytoplasmic tyrosine kinase that propagates BCR signals to phospholipase C gamma 2 (PLCγ2), calcium flux, and NF-κB activation. Regulation of this step determines the strength and duration of BCR signaling.
Negative regulation by phosphatases and ubiquitin ligases
In simple terms: Brakes are applied to prevent excessive signaling.
Phosphatases such as SHP-1 (PTPN6) remove activating phosphates from BCR signaling components, while ubiquitin ligases target signaling proteins for degradation. KLHL14 is a tumor suppressor that regulates BCR-dependent NF-κB signaling, and its loss enhances BCR-driven survival signals. These negative regulators are integral to GO:0050855.
MicroRNA and transcriptional control of BCR signaling
In simple terms: Gene expression programs adjust how much signaling machinery is available.
MicroRNAs regulate B cell receptor signaling by targeting mRNAs encoding kinases, adaptors, and transcription factors. Transcriptional programs also shape memory B cell differentiation and BCR responsiveness. Thus, regulation of BCR signaling occurs at both post-translational and gene expression levels.
Integration with NF-κB and survival pathways
In simple terms: BCR signals feed into survival and inflammatory programs.
BCR engagement activates NF-κB, which promotes B cell survival and proliferation. KLHL14 negatively regulates BCR-dependent NF-κB signaling, linking this GO term to lymphomagenesis. Glucocorticoids can modulate these pathways in aggressive lymphomas, highlighting therapeutic relevance.
Key Genes Involved in GO:0050855 regulation of B cell receptor signaling pathway
The following genes and proteins are established regulators or core components of B cell receptor signaling under GO:0050855.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD79A | Igα signaling subunit of the BCR; ITAM phosphorylation | Essential for BCR surface expression and signal initiation |
| CD79B | Igβ signaling subunit of the BCR; ITAM phosphorylation | Mutations and expression changes in B cell malignancies |
| BTK | Tyrosine kinase propagating BCR signals to PLCγ2 and NF-κB | Target of ibrutinib and other inhibitors in B cell cancers |
| SYK | Spleen tyrosine kinase recruited to phosphorylated ITAMs | Central mediator of BCR signaling; drug target |
| LYN | Src-family kinase phosphorylating BCR ITAMs | Both positive and negative regulatory roles |
| PTPN6 | SHP-1 phosphatase negatively regulating BCR signaling | Autoimmunity and lymphoma models |
| KLHL14 | Ubiquitin ligase regulating BCR-dependent NF-κB | Tumor suppressor in B cell lymphoma |
| CARD11 | Scaffold protein activating NF-κB downstream of BCR | Mutations in diffuse large B cell lymphoma |
| MALT1 | Paracaspase in the CBM complex downstream of BCR | Therapeutic target in B cell lymphomas |
| BCL10 | CBM complex component activating NF-κB | Required for BCR-induced NF-κB |
| PIK3CD | PI3K delta generating PIP3 downstream of BCR | Targeted by idelalisib in CLL |
| PRKCB | Protein kinase C beta mediating BCR signals | Involved in B cell activation and survival |
| NFKB1 | Transcription factor downstream of BCR | Controls survival and inflammatory genes |
| MIR155 | MicroRNA regulating BCR signaling components | OncomiR in B cell malignancies |
| MIR146A | MicroRNA fine-tuning BCR signaling | Autoimmunity and lymphoma |
| POU2AF1 | Transcriptional coactivator in B cells | Memory B cell differentiation |
| BCL6 | Transcriptional repressor in germinal center B cells | Memory B cell differentiation |
| PRDM1 | Transcriptional regulator of plasma cell differentiation | Downstream of BCR signaling |
How Is regulation of B cell receptor signaling pathway Regulated?
Regulation of BCR signaling is achieved through reversible phosphorylation by kinases and phosphatases, ubiquitin-mediated degradation, and microRNA-mediated control of signaling component abundance. For example, BTK activity is required for downstream NF-κB activation, while KLHL14 restricts BCR-dependent NF-κB signaling. MicroRNAs such as miR-155 and miR-146a modulate BCR signaling strength and duration. Transcriptional programs also influence BCR responsiveness during memory B cell differentiation.
regulation of B cell receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| BTK | B cell malignancies; BCR signaling | Knockout and point-mutation models; inhibitor studies |
| KLHL14 | B cell lymphoma; NF-κB regulation | Knockout and overexpression models |
| CD79A | Agammaglobulinemia; BCR assembly | Knock-in of patient mutations |
| CD79B | B cell lymphoma; BCR signaling | Knockout and knock-in models |
| MIR155 | B cell lymphoma; autoimmunity | Overexpression and knockout models |
B cell malignancies
Constitutive or enhanced BCR signaling supports survival and proliferation of malignant B cells in chronic lymphocytic leukemia and diffuse large B cell lymphoma. BTK inhibitors and PI3K delta inhibitors disrupt these signals and are used clinically. Loss of negative regulators such as KLHL14 further amplifies BCR-dependent NF-κB signaling.
Autoimmunity
Defective negative regulation of BCR signaling can lower the threshold for B cell activation and contribute to autoantibody production. MicroRNA dysregulation has been implicated in autoimmune conditions by altering BCR signaling thresholds.
Immunodeficiency
Mutations affecting BCR signaling components, including CD79A and CD79B, can cause agammaglobulinemia and impaired antibody responses. Proper regulation of GO:0050855 is therefore essential for protective humoral immunity.
Therapeutic modulation in lymphoma
Glucocorticoids modulate molecular targets within BCR signaling pathways, contributing to their efficacy in aggressive lymphomas. This highlights the clinical importance of understanding regulation of BCR signaling.
From regulation of B cell receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate regulator enhance BCR signaling? | CRISPR knockout in B cell lines |
| Does a specific point mutation in BTK alter kinase activity? | CRISPR point mutation knock-in |
| Does a disease-associated variant affect BCR signaling? | Knock-in of the variant allele |
| Where does a regulator localize during BCR activation? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of a microRNA modulate BCR signaling? | CRISPR overexpression or lentiviral overexpression |
| Which genes regulate BCR-dependent NF-κB activation? | CRISPR library screening |
How to Study the regulation of B cell receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-flow cytometry | Phosphorylation of signaling proteins | Quantify BCR signaling strength |
| Immunoblotting | Protein phosphorylation and abundance | Validate signaling changes |
| Calcium flux assay | Intracellular calcium mobilization | Assess BCR-induced activation |
| NF-κB reporter assay | NF-κB transcriptional activity | Measure downstream BCR signaling |
| CRISPR knockout screening | Gene requirement for BCR signaling | Discover regulators |
| RNA-seq | Transcriptional changes after BCR activation | Identify gene expression programs |
| MicroRNA profiling | MicroRNA expression changes | Study microRNA regulation of BCR signaling |
| Proteomics | Protein interactions and modifications | Map BCR signalosome components |
Phospho-flow and immunoblotting
Phospho-specific flow cytometry and immunoblotting measure phosphorylation of BCR-proximal signaling proteins such as SYK, BTK, and PLCγ2 after BCR cross-linking. These methods quantify the strength and kinetics of signaling regulated under GO:0050855.
Calcium flux assays
Calcium mobilization assays using fluorescent dyes measure downstream BCR signaling after antigen receptor cross-linking. They are widely used to assess regulators of BCR signaling.
NF-κB reporter assays
NF-κB luciferase reporters quantify BCR-dependent NF-κB activation, a key downstream output regulated by KLHL14 and other factors. This approach links GO:0050855 to transcriptional responses.
CRISPR screening and functional genomics
Pooled CRISPR knockout screens can identify positive and negative regulators of BCR signaling and NF-κB activation. Such screens are powerful for discovering new components of GO:0050855.
How CRISPR Can Be Used to Study GO:0050855 regulation of B cell receptor signaling pathway
Knockout
CRISPR knockout of candidate genes such as KLHL14 or BTK allows researchers to test whether they are required for BCR signaling. Knockout models can reveal positive or negative regulatory roles within GO:0050855.
Point Mutation
CRISPR point mutation knock-in can model disease-associated variants in BCR signaling genes, such as BTK mutations that alter kinase activity or inhibitor sensitivity. These models help dissect molecular mechanisms of regulation.
Knock-in
Knock-in of tagged or reporter alleles enables visualization and tracking of BCR signaling components in live cells. Knock-in of patient-derived mutations in CD79A or CD79B can model immunodeficiency or lymphoma.
Overexpression
CRISPR overexpression or lentiviral overexpression of microRNAs such as miR-155 can test gain-of-function effects on BCR signaling. Overexpression models complement knockout studies to establish causality.
How EDITGENE Supports regulation of B cell receptor signaling pathway Research
Researchers studying regulation of B cell receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in modulating BCR signaling. EDITGENE provides CRISPR-based cell model services to enable such functional studies with high specificity and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for regulation of B cell receptor signaling pathway research.
Frequently Asked Questions About regulation of B cell receptor signaling pathway
What is GO:0050855?
GO:0050855 is the Gene Ontology term for regulation of B cell receptor signaling pathway, defined as any process that modulates the frequency, rate or extent of signaling pathways initiated by cross-linking of an antigen receptor on a B cell.
What genes are involved in regulation of B cell receptor signaling pathway?
Key genes include CD79A, CD79B, BTK, SYK, LYN, PTPN6, KLHL14, CARD11, MALT1, BCL10, PIK3CD, and microRNAs such as MIR155 and MIR146A.
Why is regulation of B cell receptor signaling important?
It controls B cell activation, survival, and antibody responses, and its dysregulation contributes to B cell malignancies, autoimmunity, and immunodeficiency.
What diseases are linked to B cell receptor signaling dysregulation?
Chronic lymphocytic leukemia, diffuse large B cell lymphoma, autoimmune diseases, and agammaglobulinemia are linked to altered BCR signaling.
How is BCR signaling negatively regulated?
Phosphatases such as SHP-1 and ubiquitin ligases such as KLHL14 remove or degrade activating signals, while microRNAs tune component abundance.
What is the role of BTK in BCR signaling?
BTK is a tyrosine kinase that propagates BCR signals to downstream pathways including NF-κB, and it is a validated drug target in B cell malignancies.
How can CRISPR be used to study BCR signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate regulators of BCR signaling.
What methods measure BCR signaling activity?
Phospho-flow cytometry, immunoblotting, calcium flux assays, and NF-κB reporter assays are commonly used.
What is the role of microRNAs in BCR signaling?
MicroRNAs such as miR-155 and miR-146a regulate BCR signaling by targeting mRNAs encoding signaling components.
How does KLHL14 regulate BCR signaling?
KLHL14 is a tumor suppressor ubiquitin ligase that negatively regulates BCR-dependent NF-κB signaling.
Conclusion
GO:0050855, regulation of B cell receptor signaling pathway, is a critical biological process that governs B cell activation and humoral immunity. Its dysregulation underlies B cell malignancies, autoimmunity, and immunodeficiency, making it a rich area for therapeutic and functional genomics research. CRISPR-based models and functional assays provide powerful tools to dissect the regulators within this pathway and translate findings into clinical applications.
References
- 1. Tanaka S et al.. 2020. B Cell Receptor Signaling.. Adv Exp Med Biol 1254:23-36 PMID: 32323266
- 2. Borbet TC et al.. 2021. MicroRNA regulation of B cell receptor signaling.. Immunol Rev 304(1):111-125 PMID: 34523719
- 3. Laidlaw BJ et al.. 2021. Transcriptional regulation of memory B cell differentiation.. Nat Rev Immunol 21(4):209-220 PMID: 33024284
- 4. Tkachenko A et al.. 2023. B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells.. Int J Mol Sci 25(1) PMID: 38203179
- 5. Choi J et al.. 2020. Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.. Proc Natl Acad Sci U S A 117(11):6092-6102 PMID: 32127472
- 6. Pal Singh S et al.. 2018. Role of Bruton's tyrosine kinase in B cells and malignancies.. Mol Cancer 17(1):57 PMID: 29455639
- 8. Choi J et al.. 2024. Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas.. Cancer Cell 42(5):833-849.e12 PMID: 38701792
